Sort
261,768 grants matching “gene therapy”
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
$999,425Teodora Nicola · Alveolus Bio, Inc. · R44 · FY2024 · HL
Antithrombotic Protein C Activator for Hemodialysis
$999,415Erik Ian Tucker · Aronora, Inc. · R44 · FY2022 · HL
Antithrombotic Protein C Activator for Hemodialysis
$999,415Erik Ian Tucker · Aronora, Inc. · R44 · FY2023 · HL
A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease
$999,402Kiarash Emami · Polarean, Inc. · R44 · FY2018 · HL
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
$999,396Terry Roemer · Prokaryotics, Inc. · R44 · FY2022 · AI
Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections
$999,394Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2023 · AI
Homology-directed repair: BRCA2 and RAD51 paralogs
$999,388Maria Jasin · Sloan-Kettering Inst Can Research · R35 · FY2023 · CA
Homology-directed repair: BRCA2 and RAD51 paralogs
$999,388Maria Jasin · Sloan-Kettering Inst Can Research · R35 · FY2022 · CA
Next Generation Smart Nanoparticles
$999,338Paul Alivisatos · Stanford University · U54 · FY2011 · CA
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2022 · CA
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2021 · CA
i-AKC: Integrated AIRR Knowledge Commons
$999,330Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2023 · AI
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis
$999,317Ke Xu · Yale University · R01 · FY2025 · DA
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds
$999,289Gautam Sudhir Ghatnekar · Xequel Bio, Inc. · R44 · FY2014 · DK
PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments
$999,283Archis Bagati · Pyrojas Inc · R44 · FY2025 · CA
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
$999,274Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2019 · DK
Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from FFPE tumor biopsies
$999,273Siddarth Selvaraj · Arima Genomics, Inc. · R44 · FY2020 · CA
Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from FFPE tumor biopsies
$999,273Siddarth Selvaraj · Arima Genomics, Inc. · R44 · FY2021 · CA
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
$999,250Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2020 · CA
Rational Integration of Polygenic Risk Scores (RIPS)
$999,221Josh F. Peterson · Vanderbilt University Medical Center · R01 · FY2022 · HG
Humanized monoclonal antibodies to treat mucormycosis
$999,218Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2025 · AI
Protein Modifications Involved in Cell Signaling
$999,153Aleksandra Nita-Lazar · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Excitotoxicity in Circulatory Arrest ? Brain Injury
$999,087William Anthony Baumgartner · Johns Hopkins University · R01 · FY2011 · HL
Excitotoxicity in Circulatory Arrest ? Brain Injury
$999,087William Anthony Baumgartner · Johns Hopkins University · R01 · FY2012 · HL
SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MT
$999,002David Chimento · Rockland Immunochemicals, Inc. · N44 · FY2011 · CA